The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis

Celia C. Kamath, Hilal Maradit Kremers, David J. Vanness, W. Michael O'Fallon, Rosa L. Cabanela, Sherine E. Gabriel

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective: The objective of this study was to conduct an economic evaluation of rofecoxib and celecoxib compared with high-dose acetaminophen or ibuprofen with and without misoprostol for patients with symptomatic knee osteoarthritis (OA). Methods: A decision analysis model was designed over 6 months using two measures of effectiveness: 1) number of upper gastrointestinal (GI) adverse events averted; and 2) number of patients who achieved perceptible pain relief. Separate analyses were conducted for all patients and for those who did not respond to acetaminophen. Outcome probabilities were obtained from a comprehensive review of randomized controlled trials and observational studies. Costs were derived from actual resource utilization of OA patients. Results: In terms of averting GI events, acetaminophen dominates the other options for an average risk patient population. For patients who did not respond to acetaminophen, rofecoxib had the lowest incremental cost-effectiveness ratio (ICER) per GI event avoided ($32,000) relative to ibuprofen. In terms of pain control, ibuprofen had an ICER of $610.77 per additional patient achieving minimal perceptible clinical improvement (MPCI) relative to acetaminophen, while rofecoxib had an ICER of $12,000 relative to ibuprofen. For patients who did not respond to acetaminophen and who are at high risk of developing an adverse GI event, rofecoxib dominates ibuprofen as the preferred alternative for both measures of effectiveness. One-way, two-way, and probabilistic sensitivity analyses established that these results were generally robust. Conclusions: Our results suggest that for average-risk knee OA patients, acetaminophen dominates the other therapies in terms of cost per GI event averted. In terms of pain relief, cost-effectiveness acceptability curves indicate that if one values pain relief below $275 per patient achieving MPCI, acetaminophen is the therapy most likely to be optimal; between $275 and $14,150, ibuprofen is most likely to be optimal; and above $14,150, rofecoxib is most likely to be optimal.

Original languageEnglish (US)
Pages (from-to)144-157
Number of pages14
JournalValue in Health
Volume6
Issue number2
DOIs
StatePublished - Jan 1 2003

Fingerprint

Knee Osteoarthritis
Cyclooxygenase 2 Inhibitors
Non-Steroidal Anti-Inflammatory Agents
Acetaminophen
Cost-Benefit Analysis
Ibuprofen
Therapeutics
Pain
Celecoxib
Costs and Cost Analysis
Misoprostol
Decision Support Techniques
Osteoarthritis
Observational Studies
Randomized Controlled Trials
rofecoxib

All Science Journal Classification (ASJC) codes

  • Health Policy
  • Public Health, Environmental and Occupational Health

Keywords

  • Acetaminophen
  • Cost-effectiveness
  • Knee osteoarthritis
  • NSAIDs
  • Selective COX-2 inhibitors

Cite this

Kamath, Celia C. ; Kremers, Hilal Maradit ; Vanness, David J. ; O'Fallon, W. Michael ; Cabanela, Rosa L. ; Gabriel, Sherine E. / The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. In: Value in Health. 2003 ; Vol. 6, No. 2. pp. 144-157.
@article{5b1e310493e54245ab66da48cd734851,
title = "The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis",
abstract = "Objective: The objective of this study was to conduct an economic evaluation of rofecoxib and celecoxib compared with high-dose acetaminophen or ibuprofen with and without misoprostol for patients with symptomatic knee osteoarthritis (OA). Methods: A decision analysis model was designed over 6 months using two measures of effectiveness: 1) number of upper gastrointestinal (GI) adverse events averted; and 2) number of patients who achieved perceptible pain relief. Separate analyses were conducted for all patients and for those who did not respond to acetaminophen. Outcome probabilities were obtained from a comprehensive review of randomized controlled trials and observational studies. Costs were derived from actual resource utilization of OA patients. Results: In terms of averting GI events, acetaminophen dominates the other options for an average risk patient population. For patients who did not respond to acetaminophen, rofecoxib had the lowest incremental cost-effectiveness ratio (ICER) per GI event avoided ($32,000) relative to ibuprofen. In terms of pain control, ibuprofen had an ICER of $610.77 per additional patient achieving minimal perceptible clinical improvement (MPCI) relative to acetaminophen, while rofecoxib had an ICER of $12,000 relative to ibuprofen. For patients who did not respond to acetaminophen and who are at high risk of developing an adverse GI event, rofecoxib dominates ibuprofen as the preferred alternative for both measures of effectiveness. One-way, two-way, and probabilistic sensitivity analyses established that these results were generally robust. Conclusions: Our results suggest that for average-risk knee OA patients, acetaminophen dominates the other therapies in terms of cost per GI event averted. In terms of pain relief, cost-effectiveness acceptability curves indicate that if one values pain relief below $275 per patient achieving MPCI, acetaminophen is the therapy most likely to be optimal; between $275 and $14,150, ibuprofen is most likely to be optimal; and above $14,150, rofecoxib is most likely to be optimal.",
keywords = "Acetaminophen, Cost-effectiveness, Knee osteoarthritis, NSAIDs, Selective COX-2 inhibitors",
author = "Kamath, {Celia C.} and Kremers, {Hilal Maradit} and Vanness, {David J.} and O'Fallon, {W. Michael} and Cabanela, {Rosa L.} and Gabriel, {Sherine E.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1046/j.1524-4733.2003.00215.x",
language = "English (US)",
volume = "6",
pages = "144--157",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "2",

}

The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. / Kamath, Celia C.; Kremers, Hilal Maradit; Vanness, David J.; O'Fallon, W. Michael; Cabanela, Rosa L.; Gabriel, Sherine E.

In: Value in Health, Vol. 6, No. 2, 01.01.2003, p. 144-157.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis

AU - Kamath, Celia C.

AU - Kremers, Hilal Maradit

AU - Vanness, David J.

AU - O'Fallon, W. Michael

AU - Cabanela, Rosa L.

AU - Gabriel, Sherine E.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Objective: The objective of this study was to conduct an economic evaluation of rofecoxib and celecoxib compared with high-dose acetaminophen or ibuprofen with and without misoprostol for patients with symptomatic knee osteoarthritis (OA). Methods: A decision analysis model was designed over 6 months using two measures of effectiveness: 1) number of upper gastrointestinal (GI) adverse events averted; and 2) number of patients who achieved perceptible pain relief. Separate analyses were conducted for all patients and for those who did not respond to acetaminophen. Outcome probabilities were obtained from a comprehensive review of randomized controlled trials and observational studies. Costs were derived from actual resource utilization of OA patients. Results: In terms of averting GI events, acetaminophen dominates the other options for an average risk patient population. For patients who did not respond to acetaminophen, rofecoxib had the lowest incremental cost-effectiveness ratio (ICER) per GI event avoided ($32,000) relative to ibuprofen. In terms of pain control, ibuprofen had an ICER of $610.77 per additional patient achieving minimal perceptible clinical improvement (MPCI) relative to acetaminophen, while rofecoxib had an ICER of $12,000 relative to ibuprofen. For patients who did not respond to acetaminophen and who are at high risk of developing an adverse GI event, rofecoxib dominates ibuprofen as the preferred alternative for both measures of effectiveness. One-way, two-way, and probabilistic sensitivity analyses established that these results were generally robust. Conclusions: Our results suggest that for average-risk knee OA patients, acetaminophen dominates the other therapies in terms of cost per GI event averted. In terms of pain relief, cost-effectiveness acceptability curves indicate that if one values pain relief below $275 per patient achieving MPCI, acetaminophen is the therapy most likely to be optimal; between $275 and $14,150, ibuprofen is most likely to be optimal; and above $14,150, rofecoxib is most likely to be optimal.

AB - Objective: The objective of this study was to conduct an economic evaluation of rofecoxib and celecoxib compared with high-dose acetaminophen or ibuprofen with and without misoprostol for patients with symptomatic knee osteoarthritis (OA). Methods: A decision analysis model was designed over 6 months using two measures of effectiveness: 1) number of upper gastrointestinal (GI) adverse events averted; and 2) number of patients who achieved perceptible pain relief. Separate analyses were conducted for all patients and for those who did not respond to acetaminophen. Outcome probabilities were obtained from a comprehensive review of randomized controlled trials and observational studies. Costs were derived from actual resource utilization of OA patients. Results: In terms of averting GI events, acetaminophen dominates the other options for an average risk patient population. For patients who did not respond to acetaminophen, rofecoxib had the lowest incremental cost-effectiveness ratio (ICER) per GI event avoided ($32,000) relative to ibuprofen. In terms of pain control, ibuprofen had an ICER of $610.77 per additional patient achieving minimal perceptible clinical improvement (MPCI) relative to acetaminophen, while rofecoxib had an ICER of $12,000 relative to ibuprofen. For patients who did not respond to acetaminophen and who are at high risk of developing an adverse GI event, rofecoxib dominates ibuprofen as the preferred alternative for both measures of effectiveness. One-way, two-way, and probabilistic sensitivity analyses established that these results were generally robust. Conclusions: Our results suggest that for average-risk knee OA patients, acetaminophen dominates the other therapies in terms of cost per GI event averted. In terms of pain relief, cost-effectiveness acceptability curves indicate that if one values pain relief below $275 per patient achieving MPCI, acetaminophen is the therapy most likely to be optimal; between $275 and $14,150, ibuprofen is most likely to be optimal; and above $14,150, rofecoxib is most likely to be optimal.

KW - Acetaminophen

KW - Cost-effectiveness

KW - Knee osteoarthritis

KW - NSAIDs

KW - Selective COX-2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0037355777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037355777&partnerID=8YFLogxK

U2 - 10.1046/j.1524-4733.2003.00215.x

DO - 10.1046/j.1524-4733.2003.00215.x

M3 - Article

C2 - 12641865

AN - SCOPUS:0037355777

VL - 6

SP - 144

EP - 157

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 2

ER -